<DOC>
	<DOC>NCT01753570</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.</brief_summary>
	<brief_title>Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Genotype 1 or 2, chronic hepatitis C, with depression(including the past) treatmentnaïve or patient who have ever had previous treatment Able and willing to follow contraception requirements Cirrhosis of the liver or hepatic failure Hepatitis B surface antigenpositive or HIV antibodiespositive History of, or concurrent hepatocellular carcinoma History of, or concurrent serious depression, schizophrenia,; or suicide attempt in the past Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Feron</keyword>
</DOC>